Abstract:Photoactive prodrugs offer potential for spatially-selective antitumour activity with minimal effects on normal tissues. Excited-state chemistry can induce novel effects on biochemical pathways and combat resistance to conventional drugs. Photoactive metal complexes in particular, have a rich and relatively unexplored photochemistry, especially an ability to undergo facile intersystem crossing and populate triplet states. We have conjugated the photoactive octahedral Pt( IV ) complex trans , trans , trans -[Pt(N 3 ) 2 (OH) 2 (py) 2 ] to ferrocene to introduce novel features into a candidate photochemotherapeutic drug. The X-ray crystal structure of the conjugate Pt-Fe confirmed the axial coordination of a ferrocene carboxylate, with Pt( IV ) and Fe( II ) 6.07 Å apart. The conjugation of ferrocene red-shifted the absorption spectrum and ferrocene behaves as a light antenna allowing charge transfer from iron to platinum, promoting the photoactivation of Pt-Fe with light of longer wavelength. Cancer cellular accumulation is enhanced, and generation of reactive species is catalysed after photoirradiation, introducing ferroptosis as a contribution towards the cell-death mechanism. TDDFT calculations were performed to shed light on the behaviour of Pt-Fe when it is irradiated. Intersystem spin-crossing allows the formation of triplet states centred on both metal atoms. The dissociative nature of triplet states confirms that they can be involved in ligand detachment due to irradiation. The Pt( II ) photoproducts mainly retain the trans -{Pt(py) 2 } 2+ fragment. Visible light irradiation gives rise to micromolar activity for Pt-Fe towards ovarian, lung, prostate and bladder cancer cells under both normoxia and hypoxia, and some photoproducts appear to retain Pt( IV )–Fe( II ) conjugation.

Highly photoactive Ir(III)–Pt(IV) heterometallic conjugates for anticancer therapy

A Photodynamic and Photochemotherapeutic Platinum‐Iridium Charge‐Transfer Conjugate for Anticancer Therapy

Tuning the photoactivated anticancer activity of Pt(iv) compounds via distant ferrocene conjugation

Rational design of iridium-porphyrin conjugates for novel synergistic photodynamic and photothermal therapy anticancer agents

Anticancer activity and mechanism studies of photoactivated iridium(III) complexes toward lung cancer A549 cells

Transition metal complexes as photosensitizers for integrated cancer theranostic applications

Facile one-pot synthesis of Ir(III) Bodipy polymeric gemini nanoparticles for tumor selective NIR photoactivated anticancer therapy

Lysosome-targeted Cyclometalated Ir(III) Complexes as Photosensitizer/Photoredox Catalysis for Cancer Therapy

Bithiophene‐Functionalized Infrared Two‐Photon Absorption Metal Complexes as Single‐Molecule Platforms for Synergistic Photodynamic, Photothermal, and Chemotherapy

Pt(IV) Prodrug Photoactivation: A Promising Strategy for Cancer Therapy

In-vitro and In-vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts

Cyclometalated Ir(III) Complexes as Lysosome-Targeted Photodynamic Anticancer Agents

Cyclometalated iridium(iii) complex nanoparticles for mitochondria-targeted photodynamic therapy

An AIE-based Monofunctional Pt(ii) Complex for Photodynamic Therapy Through Synergism of Necroptosis–ferroptosis

High Photocytotoxicity Iridium(III) Complex Photosensitizer for Photodynamic Therapy Induces Antitumor Effect Through GPX4‐Dependent Ferroptosis

Aggregation-induced emission-active iridium (III)-based mitochondria-targeting nanoparticle for two-photon imaging-guided photodynamic therapy

Mitochondria-targeted cyclometalated iridium (III) complex for H2S-responsive intracellular redox regulation as potent photo-oxidation anticancer agent

Imaging of a Clickable Anticancer Iridium Catalyst.

Cyclometalated iridium(III) dithioformic acid complexes as mitochondria-targeted imaging and anticancer agents

3D CoPt nanostructures hybridized with iridium complexes for multimodal imaging and combined photothermal-chemotherapy

Amphiphilic Gemini Iridium(III) Complex as a Mitochondria-Targeted Theranostic Agent for Tumor Imaging and Photodynamic Therapy